Dupilumab treatment reduces serum SCCA2 levels in patients with atopic dermatitis

被引：0
|
作者：
Kita, Kanako [1 ]
Imai, Yasutomo [1 ,2 ]
Nagai, Makoto [1 ]
Natsuaki, Masaru [1 ]
Kanazawa, Nobuo [1 ]
机构：
[1] Hyogo Med Univ, Dept Dermatol, 1-1 Mukogawa Cho, Nishinomiya, Hyogo 6638501, Japan
[2] Imai Adult & Pediat Dermatol, Osaka, Japan
来源：
JOURNAL OF CUTANEOUS IMMUNOLOGY AND ALLERGY | 2023年 / 6卷 / 03期
基金：
日本学术振兴会;
关键词：
D O I：
10.1002/cia2.12282
中图分类号：
R392 [医学免疫学];
学科分类号：
100102 ;
摘要：
Dupilumab treatment reduced serum SCCA2 levels in patients with atopic dermatitis. Interestingly, even though the skin eruptions had not yet fully disappeared, serum SCCA2 levels were reduced well to below normal by the administration of dupilumab.
引用
收藏
页码：100 / 101
页数：2
相关论文
共 50 条
  • [1] Serum TARC and SCCA2 Levels In Infantile Atopic Dermatitis: Associations with Atopy and Severity
    Berber, Ilkay Bahar Balaban
    Koksal, Zeynep Gulec
    Yilmaz, Mustafa
    Omurlu, Imran Kurt
    Uysal, Pinar
    Erge, Duygu
    ASTHMA ALLERGY IMMUNOLOGY, 2024, 22 (02): : 153 - 160
  • [2] SCCA2 is a reliable biomarker for evaluating pediatric atopic dermatitis
    Nagao, Mizuho
    Inagaki, Shinichiro
    Kawano, Toshiki
    Azuma, Yoshinori
    Nomura, Noriko
    Noguchi, Yasuhiko
    Ohta, Shoichiro
    Kawaguchi, Atsushi
    Odajima, Hiroshi
    Ohya, Yukihiro
    Fujisawa, Takao
    Izuhara, Kenji
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2018, 141 (05) : 1934 - +
  • [3] The usefulness of SCCA2 and periostin as clinical biomarkers for severe adult atopic dermatitis
    Fujimoto, R. F.
    Kataoka, Y. K.
    Kishida, H. K.
    Sachiko, S. S.
    Shigyou, A. S.
    Yoshioka, E. Y.
    Tonomura, K. T.
    Okuda, E. O.
    Izuhara, K. I.
    BRITISH JOURNAL OF DERMATOLOGY, 2018, 179 (01) : E51 - E52
  • [4] Clinical utility of new biomarkers, periostin and SCCA1/SCCA2, in childhood asthma and atopic dermatitis
    Hirayama, J.
    Kainuma, K.
    Nagao, M.
    Fujisawa, T.
    Ohta, S.
    Izuhara, K.
    ALLERGY, 2015, 70 : 55 - 55
  • [5] Serum squamous cell carcinoma antigen-2 (SCCA2) is a reliable biomarker for detecting the clinical severity of atopic dermatitis in children
    Inagaki, S.
    Nagao, M.
    Narita, M.
    Kawano, T.
    Azuma, Y.
    Nomura, N.
    Noguchi, Y.
    Odajima, H.
    Fujisawa, T.
    Ohya, Y.
    Izuhara, K.
    ALLERGY, 2018, 73 : 730 - 730
  • [6] Dupilumab in the Treatment of Cheilitis in Atopic Dermatitis Patients
    Shan, Jinpeng
    Ali, Kamran
    Da, Jiayang
    Li, Menghua
    Qiu, Yunmi
    Lou, HaiYue
    Wu, Liming
    CLINICAL COSMETIC AND INVESTIGATIONAL DERMATOLOGY, 2022, 15 : 2437 - 2443
  • [7] SCCA, SCCA1 and SCCA2 in cervical cancer patients
    Jan, Kulpa
    Rychlik, U.
    Jakubowicz, J.
    Einarsson, R.
    Rusiecka, G.
    Sedlaczek, P.
    TUMOR BIOLOGY, 2006, 27 : 113 - 113
  • [8] Serum dupilumab levels after 16 weeks of treatment are not associated with treatment response or side effects in atopic dermatitis patients
    Spekhorst, L.
    de Graaf, M.
    Loeff, F.
    Zuithoff, N.
    Bakker, D.
    Boesjes, C.
    Thijs, J.
    Achten, R.
    van Wijk, F.
    Rispens, T.
    de Bruin-Weller, M.
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2022, 142 (12) : S201 - S201
  • [9] Dupilumab for treatment of atopic dermatitis
    Seegraeber, Marlene
    Srour, Jerome
    Walter, Alexandra
    Knop, Macarena
    Wollenberg, Andreas
    EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2018, 11 (05) : 467 - 474
  • [10] Dupilumab for the Treatment of Atopic Dermatitis
    Ferreira, S.
    Torres, T.
    ACTAS DERMO-SIFILIOGRAFICAS, 2018, 109 (03): : 230 - 240
12345